Scientists propose strategy for site-selective chiral drug synthesis in living systems

June 26, 2020

Enantioselectivity plays an important role in the pharmacological and toxicological processes of chiral drugs.

In chiral drug synthesis that uses bioorthogonal chemistry within complex biological milieu, asymmetric transfer hydrogenation (ATH), which utilizes safe hydrogen donors instead of high pressure H2, has been gaining popularity and has been performed in living cells.

Prof. QU Xiaogang from the Changchun Institute of Applied Chemistry (CIAC) of the Chinese Academy of Sciences and his colleagues recently presented a novel strategy using a neutrophil-directed ATH reaction to achieve site-selective chiral drug synthesis in living systems.

The study was published in Chem on June 25.

The researchers first constructed inflammation-targeted chiral catalysts by preparing Pd-immobilized mesoporous silica nanoparticles (MSN-Pd).

Cinchona alkaloid enantiomers were individually adsorbed on the MSN-Pd catalyst to introduce enantioselectivity.

A neutrophil membrane was subsequently coated onto the MSN-Pd chiral catalysts, creating the MSN-Pd/CD@Neu catalyst, which possessed inflammation-targeting ability inherited from the neutrophils.

The next stage of research involved using MSN-Pd/CD@Neu to catalyze an intracellular conversion involving the precursors of Ibuprofen (IBU).

IBU is a drug well-known for relieving inflammation, fever and pain. The pharmacological activity of IBU is mainly attributed to the S-enantiomer while the R-enantiomer is thought to be potentially harmful. For this reason, it is important to be able to control the catalysis of IBU into its enantiomers.

In this study, the conversion of the precursor molecule of IBU (pre-IBU) to S-IBU was realized by using a targeted ATH bioorthogonal reaction in a mouse paw model, with HCOONa as the hydrogen donor.

Compared with the controls, the MSN-Pd/CD@Neu catalyst simultaneously exhibited inflammation-targeted capability and enantioselectivity as part of its anti-inflammatory action.

In situ synthesized IBU can ameliorate lipopolysaccharide (LPS)-triggered acute inflammation, pyrexia and tissue edema.

This research opens a new avenue for chiral drug synthesis activated on the designed target in living systems. It also holds promise for wide application of targeted bioorthogonal chemistry, especially in enantioselective drug synthesis.

Chinese Academy of Sciences Headquarters

Related Drug Articles from Brightsurf:

New drug that can prevent the drug resistance and adverse effects
A research team in Korea is garnering attention for having developed an anticancer drug that could potentially prevent drug resistance.

Potent drug supply drop, not domestic drug policies, likely behind 2018 OD death downturn
The slight decline in drug overdose deaths in 2018 coincides with Chinese regulations on the powerful opioid carfentanil, rather than the result of domestic U.S. efforts to curb the epidemic, a new analysis reveals.

Old drug standards delay new drug approvals
The more information the FDA has about existing drugs, the longer it takes to OK new ones for the same conditions.

What drug companies spend to bring a new drug to market
Researchers estimated the cost to bring 63 new drugs or biologics to market between 2009 and 2018 using publicly available data on research and development expenditures for these medicines.

New flu drug drives drug resistance in influenza viruses
University of Wisconsin-Madison researchers examined the effects of baloxavir treatment on influenza virus samples collected from patients before and after treatment.

Cause of drug resistance in a drug resistance in intestinal tumors identified
Researchers clarify mechanisms that allow hard-to-treat cancers to develop, and have identified strategies that could lead to new therapies.

AI could offer warnings about serious side effects of drug-drug interactions
Researchers at Penn State have developed a machine learning system that may be able to warn doctors and patients about possible negative side effects that might occur when drugs are mixed.

Charcoal-based drug delivery system improves efficacy of common herpes drug
A study led by researchers from the University of Illinois at Chicago has found that combining acyclovir -- a commonly prescribed topical herpes medication -- with particles of activated carbon improves efficacy of the drug.

Candida auris is a new drug-resistant fungus emerging globally and in the US early detection is key to controlling spread of deadly drug-resistant fungus
Early identification of Candida auris, a potentially deadly fungus that causes bloodstream and intra-abdominal infections, is the key to controlling its spread.

Arming drug hunters, chemists design new reaction for drug discovery
Colorado State University organic chemists have forged a powerful new tool for drug hunters -- a simple, elegantly designed chemical reaction that could fling open an underexplored wing of biologically relevant chemistry.

Read More: Drug News and Drug Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to